Roth Capital Reiterates “Buy” Rating for Niagen Bioscience (NASDAQ:NAGE)

Niagen Bioscience (NASDAQ:NAGE)‘s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a report issued on Friday, Marketbeat.com reports. They presently have a $23.00 price target on the stock, up from their prior price target of $10.00. Roth Capital’s target price indicates a potential upside of 70.12% from the company’s current price.

Separately, Canaccord Genuity Group began coverage on shares of Niagen Bioscience in a report on Tuesday, May 27th. They issued a “buy” rating and a $13.00 price target for the company.

Niagen Bioscience Price Performance

Shares of NASDAQ NAGE opened at $13.52 on Friday. The company has a market capitalization of $1.06 billion, a P/E ratio of 79.53 and a beta of 2.08. The business’s fifty day moving average price is $8.83. Niagen Bioscience has a twelve month low of $2.31 and a twelve month high of $13.84.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.